ABSTRACT
Treatment of pyoderma gangrenosum (PG) is challenging due to the absence of standardized guidelines and the lack of evidence-based, effective treatment options. Here, we performed a systematic review to summarize the use of biologics and their efficacy in the treatment of PG. We searched PubMed/MEDLINE, EMBASE, and Cochrane electronic databases from their inception to September 22nd, 2022, and included 82 peer-reviewed studies with a total of 108 patients. Infliximab, adalimumab, and etanercept were the most utilized biologic therapies in the treatment of PG in 64.8% (70/108), 16.7% (18/108), and 11.1% (12/108) of the cases, respectively. With respect to treatment response, 88.9% (96/108) of the patients achieved complete resolution of PG with biologic therapies. The average number of days to improvement and resolution of PG treated after starting biologic therapies was 30 and 161, respectively. PG recurred in 15.5% (11/71) of those reported the outcome. Our study suggests that biologic therapies may be an attractive therapeutic option for PG with an excellent efficacy.
Subject(s)
Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/drug therapy , Treatment Outcome , Biological Products/therapeutic use , Biological Therapy/methods , Infliximab/therapeutic use , Etanercept/therapeutic use , Adalimumab/therapeutic use , Recurrence , Dermatologic Agents/therapeutic useABSTRACT
Chronic skin ulcers in patients with suspected pyoderma gangrenosum can, on closer inspection and further workup, have a different cause. Recognition of key features on clinical examination such as the presence of atrophie blanche is key to avoid misdiagnosis of pyoderma gangrenosum and its subsequent treatment with high-dose corticosteroids and other immunosuppressive medications.
Subject(s)
Hydroxyurea , Pyoderma Gangrenosum , Thrombocythemia, Essential , Humans , Hydroxyurea/adverse effects , Hydroxyurea/therapeutic use , Thrombocythemia, Essential/drug therapy , Thrombocythemia, Essential/complications , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/pathology , Pyoderma Gangrenosum/chemically induced , Chronic Disease , Female , Skin Ulcer/pathology , Skin Ulcer/chemically induced , Aged , Leg UlcerSubject(s)
Arthritis, Rheumatoid , Azetidines , Behcet Syndrome , Purines , Pyoderma Gangrenosum , Pyrazoles , Sulfonamides , Humans , Pyrazoles/therapeutic use , Azetidines/therapeutic use , Sulfonamides/therapeutic use , Behcet Syndrome/complications , Behcet Syndrome/diagnosis , Behcet Syndrome/drug therapy , Purines/therapeutic use , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/etiology , Pyoderma Gangrenosum/diagnosis , Treatment Outcome , Female , Male , Middle AgedABSTRACT
Pyoderma gangrenosum (PG) is a sterile inflammatory skin condition that is frequently associated with immune-related diseases, including inflammatory bowel disease (IBD). PG causes noninfectious ulcers. Facial PG is uncommon while PG usually occurs on the trunk and lower limbs. Herein, we report a case of a male teenager with fever, pustules, ulcers, and necrosis on both cheeks. He was initially diagnosed with complicated acne with bacterial infection, but the condition progressed to subcutaneous ulcers despite treatment. Biopsy revealed inflammatory lesions in dermal and subcutaneous tissue with neutrophil infiltration, consistent with PG. Although lacking typical IBD symptoms, blood tests revealed anemia and positive fecal occult blood. Sigmoidoscopy revealed inflammation, ulcers, and pseudopolyps in the colon and rectum, thereby diagnosing ulcerative colitis (UC). After treating PG and UC with prednisolone and skin grafts, golimumab was prescribed. The patient is now in remission. Necrotic tissue buildup can complicate closure in PG cases;this emphasizes the need for effective IBD treatment to facilitate procedures such as skin grafts.
Subject(s)
Colitis, Ulcerative , Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/drug therapy , Male , Colitis, Ulcerative/complications , Adolescent , Facial Dermatoses/etiology , Facial Dermatoses/drug therapy , Facial Dermatoses/diagnosis , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal/administration & dosageSubject(s)
Cocaine , Drug Contamination , Levamisole , Pyoderma Gangrenosum , Humans , Levamisole/adverse effects , Pyoderma Gangrenosum/chemically induced , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/pathology , Cocaine/adverse effects , Male , Cocaine-Related Disorders/complications , Adult , FemaleABSTRACT
This case report describes a man in his 20s with psoriasis who was receiving stable treatment with adalimumab for 3 years and was diagnosed with pyoderma gangrenosum and was referred for a 6-month history of multiple inflammatory ulcers on the right dorsal foot and ankle.
Subject(s)
Antibodies, Monoclonal, Humanized , Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/diagnosis , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Humanized/administration & dosage , Female , Middle Aged , Treatment Outcome , MaleABSTRACT
Pyoderma gangrenosum (PG) is a rare inflammatory dermatologic condition with neutrophilic infiltration of the skin that causes pustules and ulcerations. Janus kinase (JAK) inhibitors are immunomodulating agents that have been recently described in the literature as an effective treatment for PG. We describe a patient with PG on the lower extremities successfully treated with baricitinib. We also conducted a narrative review of the literature of PG patients treated with JAK inhibitors who were refractory to other treatments.
Subject(s)
Azetidines , Janus Kinase Inhibitors , Purines , Pyoderma Gangrenosum , Pyrazoles , Sulfonamides , Humans , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/diagnosis , Janus Kinase Inhibitors/therapeutic use , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Azetidines/therapeutic use , Purines/therapeutic use , Female , Treatment Outcome , Skin/pathology , Skin/drug effects , Middle Aged , MaleABSTRACT
Superficial granulomatous pyoderma gangrenosum is a rare, superficial, vegetating form of pyoderma gangrenosum that tends to occur as a single lesion, most commonly on the trunk. Herein, we report a clinically confounding case of disseminated superficial granulomatous pyoderma gangrenosum in a patient with a 5-year history of painful and chronic ulcerations of the bilateral upper extremities and face in a sun exposed distribution. This was a diagnostically challenging case due to the treatment-refractory nature of our patient's skin lesions and the atypical clinical and histologic presentations encountered. We review our clinical decision process and acknowledge other entities that were considered during the clinical course of this case. Additionally, we discuss the lack of responsiveness to various treatment options with eventual successful clearance of this patient's active skin disease with initiation of adalimumab.
Subject(s)
Adalimumab , Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/pathology , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/drug therapy , Adalimumab/therapeutic use , Female , Male , Granuloma/pathology , Middle Aged , Suppuration , Dermatitis/pathology , Dermatitis/diagnosisABSTRACT
ABSTRACT: Pyoderma gangrenosum is an inflammatory skin disease that presents with rapidly progressive ulcers with violaceous, undermined borders. Despite most commonly affecting the lower extremities, pyoderma gangrenosum can rarely present in the genital, anal, and perineal regions. We describe 2 cases and report a review of published cases.
Subject(s)
Perineum , Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/pathology , Perineum/pathology , Male , Female , Adult , Anus Diseases/pathology , Middle Aged , Anal Canal/pathology , Treatment OutcomeABSTRACT
ABSTRACT: Pyoderma gangrenosum (PG) is a neutrophilic dermatosis that is challenging to diagnose and treat. Clinicians frequently use fast-acting corticosteroids, which are subsequently combined with slower-acting immunosuppressants to progressively taper the corticosteroid dosage. Current research is focused on the use of monoclonal antibodies (mAbs) directed against target molecules involved in the pathogenesis of PG. However, available data on their efficacy are based on sporadic case reports and clinical experiences, so the authors aimed to evaluate the efficacy of risankizumab, an anti-interleukin-23 mAb, in the management of two complex PG cases. The authors enrolled two patients with PG who were already treated with immunosuppressive therapies. Their management was based on the off-label use of an mAb directed against the p19 subunit of interleukin-23: risankizumab. Patients received subcutaneous injections of 150 mg at the start of treatment, at week 4, and then every 10 weeks thereafter. Systemic therapy was combined with local management of ulcers, based on the principles of TIME (tissue, infection, moisture balance, and epithelialization) applied to the inflammatory and noninflammatory phases of PG. Clinical resolution was obtained at week 24 for patient 1 and week 16 for patient 2 and was maintained until week 40, without adverse effects or disease recurrence. These clinical cases demonstrate that risankizumab is a valid tool in terms of efficacy and safety for complicated cases of multirefractory PG when provided in parallel with local personalized wound management.
Subject(s)
Antibodies, Monoclonal , Pyoderma Gangrenosum , Humans , Middle Aged , Antibodies, Monoclonal/therapeutic use , Off-Label Use , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/diagnosis , Treatment OutcomeSubject(s)
Adalimumab , Antibodies, Monoclonal, Humanized , Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/chemically induced , Pyoderma Gangrenosum/drug therapy , Adalimumab/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Female , Drug Substitution , Middle Aged , Male , Psoriasis/drug therapy , Dermatologic Agents/adverse effects , Dermatologic Agents/therapeutic useABSTRACT
We evaluated the primary application of crushed prednisolone combined with hydrocolloid powder for clinically diagnosed peristomal pyoderma gangrenosum (PPG). We present our data on this cohort and follow-up of our previous patients. Of the 23 patients who were commenced on this regime, 18 healed (78%). Twenty-two patients commenced on this regime as the primary treatment for their PPG, and for one, it was a rescue remedy after failed conventional therapy. Four patients with significant medical comorbidities failed to heal and one had their stomal reversal surgery before being fully healed. The proposed treatment regime for PPG is demonstrated to be effective, inexpensive and able to be managed in the patient's usual home environment. In vitro drug release analysis was undertaken, and data are presented to provide further insights into the efficacy of this regime.
Subject(s)
Prednisolone , Pyoderma Gangrenosum , Humans , Prednisolone/therapeutic use , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/etiology , Pyoderma Gangrenosum/diagnosis , Powders/therapeutic use , Drug Liberation , Treatment OutcomeABSTRACT
PASS syndrome is a rare autoinflammatory disease characterized by acne vulgaris, hidradenitis suppurativa, pyoderma gangrenosum, and ankylosing spondylitis. Unlike other autoinflammatory disorders such as PAPA and PASH syndrome, there is no documented gene mutation link. Although there are no established treatment guidelines due to the rarity of these diseases, systemic corticosteroids, biologics, and immunosuppressive drugs are used currently. In our report, we presented a case of PASS syndrome who was unresponsive to adalimumab and in whom we observed improvement in both skin and joint manifestations with intravenous immunoglobulin (IVIG) and anti-IL-1 treatment.
Subject(s)
Acne Vulgaris , Hidradenitis Suppurativa , Pyoderma Gangrenosum , Humans , Immunoglobulins, Intravenous/therapeutic use , Hidradenitis Suppurativa/drug therapy , Acne Vulgaris/complications , Acne Vulgaris/drug therapy , Acne Vulgaris/genetics , Syndrome , Skin , Pyoderma Gangrenosum/drug therapyABSTRACT
BACKGROUND: Over the past few decades, advances in medical research and diagnostic tools have shed light on some aspects of pyoderma gangrenosum (PG). Nevertheless, the multifactorial etiology, pathogenesis, and optimal management strategies for PG need to be further investigated. To address these knowledge gaps and contribute to a better understanding of this complex dermatological disorder, we collected epidemiological, clinical, and therapeutic aspects of a case series of PG patients occurring in our department over the past 10 years. METHODS: We performed a single-centered, retrospective, observational study analyzing all cases with a diagnosis of PG observed at the Dermatology clinic of the Fondazione Policlinico A. Gemelli IRCCS Catholic University from January 1, 2013, to January 1, 2023. For each case, we retrieved demographic data, the presence of other skin and systemic conditions, and the histopathological and clinical characteristics of PG, such as clinical variant, number of lesions, disease localization, previous therapy, response to treatment, and occurrence of relapse. RESULTS: We included 35 patients, 22 females and 13 males with a mean age of 40.0 years. Twenty patients (57.1%) had multiple localizations of disease, and the most commonly involved site was the lower limbs (85.7%). The lesions were mainly associated with inflammatory bowel diseases (51.4%) and hidradenitis suppurativa (37.1%). Clinical resolution with complete re-epithelialization was achieved in 25 patients (71.4%) with an average time of 20.8 months. On average, patients who underwent therapy with biological drugs had better outcomes. CONCLUSIONS: PG is a severe, rare, and pleomorphic disease associated with a broad spectrum of conditions. Corticosteroids remain the primary first-line approach for severe forms, but using biological immunosuppressants is promising.
Subject(s)
Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/epidemiology , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/drug therapy , Male , Female , Retrospective Studies , Adult , Middle Aged , Young Adult , Aged , Adolescent , Recurrence , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/epidemiologyABSTRACT
Pyoderma gangrenosum is a rare dermatologic disorder that disrupts the skin barrier, requiring immunosuppressive therapy. We successfully used cefiderocol for the treatment of an extensively drug-resistant Pseudomonas aeruginosa bacteremia, and presumed osteomyelitis in a patient with severe pyoderma gangrenosum and associated immunosuppressive therapy while being medically optimized for skin grafting. We obtained bone and skin/subcutaneous tissue while the patient was on cefiderocol under an institutional review board-approved biologic waste recovery protocol. Cefiderocol concentrations in bone and skin/subcutaneous tissue were 13.9 and 35.9 mcg/g, respectively. The patient recovered from bacteremia and underwent autografting without further complications. Cefiderocol at approved dosing of 2 g IV (3-hour infusion) every 8 hours resulted in bone and skin/subcutaneous tissue concentrations adequate to treat extensively drug-resistant Gram-negative bacteria that remain susceptible to cefiderocol.